May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
The Efficacy of Allegretto and Visx Custom vue Lasers in Treatment of Hyperopia
Author Affiliations & Notes
  • A. R. Nalgirkar
    Shiley Eye center, UCSD, Department of Ophthalmology, La Jolla, California
  • T. Tantayakom
    Shiley Eye center, UCSD, Department of Ophthalmology, La Jolla, California
  • T. Purcell
    Shiley Eye center, UCSD, Department of Ophthalmology, La Jolla, California
  • L. Kearsley
    Shiley Eye center, UCSD, Department of Ophthalmology, La Jolla, California
  • A. Lu
    Shiley Eye center, UCSD, Department of Ophthalmology, La Jolla, California
  • L. Garbutt
    Shiley Eye center, UCSD, Department of Ophthalmology, La Jolla, California
  • K. Lim
    Shiley Eye center, UCSD, Department of Ophthalmology, La Jolla, California
  • R. Patel
    Shiley Eye center, UCSD, Department of Ophthalmology, La Jolla, California
  • D. Schanzlin
    Shiley Eye center, UCSD, Department of Ophthalmology, La Jolla, California
  • Footnotes
    Commercial Relationships A.R. Nalgirkar, None; T. Tantayakom, None; T. Purcell, None; L. Kearsley, None; A. Lu, None; L. Garbutt, None; K. Lim, None; R. Patel, None; D. Schanzlin, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2365. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. R. Nalgirkar, T. Tantayakom, T. Purcell, L. Kearsley, A. Lu, L. Garbutt, K. Lim, R. Patel, D. Schanzlin; The Efficacy of Allegretto and Visx Custom vue Lasers in Treatment of Hyperopia. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2365.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate and compare the safety and efficacy of the Allegretto Wave Excimer Laser System (WaveLight Laser) and VISX (CustomVue Technology, AMO) in surgical correction for hyperopia and hyperopic astigmatism.

Methods:: Eighty-eight cases of low (0 to +4.0 D) hyperopia with or without astigmatism treated with the Allegretto Wave excimer laser and Visx were retrospectively evaluated for refractive correction.Patients with refractive error of + 4.00 D or better with or without astigmatism were treated with either the Allegretto or the VISX lasers. Flaps were created with the Moria microkeratome (Moria, France) or the Intralase (Intralase corp.) depending on patient preference. Parameters noted were pre- and postoperative refractive error, uncorrected visual acuity (UCVA) and the best spectacle-corrected visual acuity. The patients were followed up at 3 months and up to 6 months.

Results:: In the Allegretto group, the mean patient age was 57.8 years compared to 56.6 years in the VISX group. The mean preoperative refraction was 2.35 D for sphere and 0.04 D for the cylinder in the Allegretto group compared to 2.02 D sphere and 0.68 D cylinder for the VISX group. Of the eyes in the Allegretto group, 79.5 % were within +/-0.50 D of the refractive goal whereas 47.7 % had vision better than or equal to20/20. For the VISX group, 95.4% were within +/- 0.50 D of the refractive goal whereas 59% were better than or equal to 20/20. The Fisher’s exact test showed no difference in the two groups in relation to the patients achieving 20/20 (UCVA) vision (p=0.20). However,it did show a statistically significant difference when the postoperative refraction under + 0.50 D was considered (p < 0.001).

Conclusions:: Hyperopic correction using the WaveLight Allegretto Wave excimer laser and Visx Custom Vue both demonstrated comparable results and efficacy in treating low to moderate hyperopes in terms of visual acuity. However, Visx results showed a more predictable response in achieving a near desired refractive correction in our study.

Keywords: hyperopia • refractive surgery • laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×